Hementin-Like Protein (HLP-1)
Fibrinogenolytic / anti-platelet protein homologous to hementin — disrupts platelet aggregation.
Praeklinisch / mechanistischLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Fibrinogenolytic / anti-platelet protein homologous to hementin — disrupts platelet aggregation.
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
HLP-1 is documented mechanistically only; no human evidence. Homology to hementin does NOT establish clinical efficacy, and no FDA-approved derivative exists.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Molecular weight
- 80,000 Da
- Source species
- Haementeria-related species
- Discovered
- 2006
Biological Targets
- → fibrinogen
- → platelet aggregation
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.